A biotechnology company credited as a pioneer in RNA medicines (siRNA).
2 AI-extracted insights from 2 sources — podcasts, YouTube channels, and X/Twitter accounts.
Based on 1 scored insight about Alnylam Pharmaceuticals, Inc..
The 2 sources with the most insights about Alnylam Pharmaceuticals, Inc. on Kazuha.
AI-generated insights from podcasts, YouTube videos, and X posts — ordered by most recent.
Described as 'super cheap' and categorized as a high-conviction long position.
Credited for its decades of foundational work that led to the success of RNA therapeutics, now considered a 'de-risked modality' and a 'mature platform'.
Described as 'super cheap' and categorized as a high-conviction long position.
Credited for its decades of foundational work that led to the success of RNA therapeutics, now considered a 'de-risked modality' and a 'mature platform'.
Other assets that creators frequently mention in the same content as Alnylam Pharmaceuticals, Inc..
The most active sources covering Alnylam Pharmaceuticals, Inc. (ALNY) on Kazuha are @realmartinshkreli, Andreessen Horowitz. Kazuha aggregates AI-extracted insights from podcasts, YouTube channels, and X/Twitter accounts.
Kazuha has indexed 2 AI-extracted insights about Alnylam Pharmaceuticals, Inc. (ALNY) from 2 different sources. New insights are added whenever a covered creator publishes a new podcast episode, video, or post.
Creators covering Alnylam Pharmaceuticals, Inc. (ALNY) most frequently also discuss PLTR, HCA, THC, INSM, BMY. See the "Discussed alongside" section above for full asset pages.